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Abstract | Classic textbook neurology teaches that amyotrophic lateral sclerosis (ALS) is a degenerative 
disease that selectively affects upper and lower motor neurons and is fatal 3–5 years after onset—a description 
which suggests that the clinical presentation of ALS is very homogenous. However, clinical and postmortem 
observations, as well as genetic studies, demonstrate that there is considerable variability in the phenotypic 
expression of ALS. Here, we review the phenotypic variability of ALS and how it is reflected in familial and sporadic 
ALS, in the degree of upper and lower motor neuron involvement, in motor and extramotor involvement, and in the 
spectrum of ALS and frontotemporal dementia. Furthermore, we discuss some unusual clinical characteristics 
regarding presentation, age at onset and disease progression. Finally, we address the importance of this 
variability for understanding the pathogenesis of ALS and for the development of therapeutic strategies.
Swinnen, B. & Robberecht, W. Nat. Rev. Neurol. advance online publication 14 October 2014; doi:10.1038/nrneurol.2014.184
Introduction
Amyotrophic lateral sclerosis (ALS) is a heterogeneous 
disorder. The genetic heterogeneity is obvious, given 
the long list of genes in which mutations cause ALS.1 
Considering that the aetiology of ALS remains unknown 
in nearly 90% of cases, the true causal heterogeneity is 
likely to be even larger. The mechanistic heterogeneity 
of ALS adds to the complexity of this disorder.2 The fact 
that ALS starts in the bulbar region in some patients, 
and in the limbs in others, has always been evident to 
clinicians, and is often used as stratification parameter in 
clinical trials. Phenotypic variability goes far beyond the 
site of onset, however, and can be observed with regard 
to age at onset, familial occurrence, type of motor neuron 
involvement, extent of extramotor involvement, and 
disease duration, among other parameters. Here, we will 
review several aspects of this phenotypic heterogeneity 
of ALS and discuss some of its implications.
A student’s vignette: classic ALS
Variability in location of onset
Spinal onset
In most patients, ALS starts around the age of 60 years 
with asymmetric, painless weakness in a limb, referred 
to as spinal-onset ALS (Figure 1).3,4 Clinical examina-
tion usually reveals atrophy and weakness of muscles, 
fasciculations, hyperreflexia (or at least brisk reflexes), 
and often a mild to severe hypertonia.3 Clinicians desig-
nate weakness, muscle atrophy and fasciculations as 
lower motor neuron signs, whereas hyperreflexia and 
hypertonia indicate upper motor neuron involvement 
(Figure 2). Interestingly, the Babinski sign—also known 
as the extensor plantar reflex—is often absent, and 
hypertonia is often ‘glue-like’, reminiscent of what one 
finds in frontal or even extrapyramidal syndromes, and 
different from the clasp-knife phenomenon of the upper 
limbs in stroke and the spastic kick of the lower limbs 
in familial spastic paraparesis. Initially, the abnormal 
findings can be patchy, but the disorder spreads relent-
lessly over time. In many but not all patients, this spread 
seems contiguous, a phenomenon hypothesized by some 
authors to reflect the spread at the cellular level.5
Bulbar onset
In about 20% of patients with ALS, the weakness starts in 
bulbar muscles, with dysarthria, dysphagia and tongue 
fasciculations (Figure 2).3,6 A brisk jaw jerk is often found 
in these patients, and pseudobulbar affect (an inaccurate 
term mainly referring to uncontrolled crying or laugh-
ing) is sometimes present. The presence of limb hyper-
reflexia suggests that the disease has already spread. 
Bulbar-onset ALS was originally considered to be a dif-
ferent disease from ALS, and was termed ‘progressive 
bulbar palsy’.7
The onset of symptoms is gradual in most patients, but 
some become aware of their problems quite abruptly; 
neurol ogists often need to consider stroke and myas thenia 
in the differential diagnosis of these patients. Bulbar-
onset ALS must also be distinguished from Kennedy’s 
disease (bulbar and spinal muscular atrophy) or from 
 Brown–Vialetto–Van Laere syndrome (see below).3
Patients with bulbar-onset ALS have a worse prognosis 
than patients with spinal onset, with a mean survival of 
2 years and long-term (>10 years) survival of only 3%.6 
The poor prognosis is mostly attributable to the fact that 
patients with bulbar-onset ALS are prone to aspiration and 
nutritional problems, and is possibly also related to earlier 
respiratory dysfunction due to involvement of the cervical 
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phrenic motor neurons.8 Loss of ambulation is an ominous 
sign for these patients, indicating mean life expectancy of 
only 3 months.9 The site of onset is,  therefore, used as a 
stratification parameter in clinical trials.
Key points
 ■ Amyotrophic lateral sclerosis (ALS) is a highly heterogeneous entity
 ■ Cognitive impairment is a common feature of ALS: frontotemporal dementia 
and ALS constitute the ends of a spectrum reflecting different manifestations 
of the same pathogenic mechanism
 ■ Upper and lower motor neuron involvement is variable in ALS, and yields a 
spectrum with primary lateral sclerosis and progressive muscular atrophy at the 
two ends
 ■ In rare cases, extrapyramidal, cerebellar, sensory and autonomic systems 
can be affected in ALS, indicating that ALS should be seen as a multisystem 
neurodegenerative disease
 ■ The method and timing of assessment of a patient account for a considerable 
proportion of the clinical variability
 ■ The biology underlying the ALS phenome needs to be elucidated, as the 
pathophysiological mechanisms of the disease could be targets for therapeutic 
interventions
Respiratory onset
In about 3–5% of patients, ALS is characterized by res-
piratory onset, with orthopnoea or dyspnoea, and mild 
or even absent spinal or bulbar signs.6 Respiratory-
onset ALS has a male predominance.6,10 The prognosis 
is notori ously poor, with a mean survival of 1.4 years and 
no long-term survival.6,10
Genes and type of onset
The factors that determine the nature of ALS onset 
remain unknown. Sex hormones are suspected to con-
tribute to the type of onset because of the striking female 
predominance in bulbar-onset patients.9 Bulbar onset is 
very frequent in ALS associated with C9orf72 mutations; 
by contrast, ALS associated with mutations in super oxide 
dismutase 1 (SOD1) almost never starts in the bulbar 
motor neurons (see below). Such associations between 
the type of onset and genetic causes suggest that the site 
of onset is unlikely to merely reflect a stochastic process.
Familial versus sporadic ALS
About 10% of patients with ALS have an affected rela-
tive and are, thus, considered to have familial ALS.1 
Those who do not have an affected relative are consid-
ered to have sporadic ALS. It is likely that many if not 
all cases of familial ALS will turn out to be hereditary in 
nature, because in a growing number of the pedigrees of 
patients with familial ALS, a causal mutation is eventu-
ally identified. In some populations, such a hereditary 
cause is identifiable in nearly 80% of familial ALS cases.1 
Mutations in SOD1, TARDBP (the gene that encodes 
TAR DNA-binding protein 43 [TDP-43]), FUS and 
C9orf72 explain more than half of cases of familial ALS.1
The cause of sporadic ALS is unknown, but twin 
studies suggest that it has a genetic component as well, 
possibly in interaction with as yet unknown environmen-
tal factors.11 Some patients with sporadic ALS initially 
receive a wrong classification, as they are later found 
to have a hereditary form of the disease when they are 
found to carry a causal mutation. Reduced penetrance 
and a low number of offspring are the main explanations 
for the misclassifications,13 but other contributory factors 
include a lack of complete information of the medical 
history of the patients’ relatives, non-paternity events, 
and variability of the phenotypic expression.14 In most 
populations, nearly 10% of the patients with so-called 
sporadic ALS carry a C9orf72 mutation;1 the advanced 
age at which C9orf72-associated ALS often begins and 
unexpected variability of the phenotype associated with 
C9orf72 mutations (see below) are the main reasons why 
these patients are misclassified.
Age at onset
Although ALS usually starts in the fifth or sixth decade of 
life, onset at almost any age has been described. Juvenile 
ALS is defined as ALS with age at onset before 25 years, 
and the course of progression is generally slower than in 
other forms of ALS.15,16 Mutations in ALS2, SETX and 
FUS are well-known causes of juvenile ALS.1,14 Patients 
carrying the FUS Pro525Leu mutation have a notoriously 
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Figure 1 | Pattern of motor involvement in different ALS phenotypes. Red indicates 
LMN involvement, blue indicates UMN involvement. Darker shading indicates more‑
severe involvement. a | In spinal‑onset ALS, patchy UMN and LMN involvement 
is observed in all limbs. b | In bulbar‑onset ALS, UMN and LMN involvement is 
observed in the bulbar muscles. c | In progressive muscular atrophy, LMNs in arms 
and legs are involved, often proximally. d | In primary lateral sclerosis, UMNs of 
arms and legs are primarily involved, but later in the disease, discrete LMN 
involvement can be detected. e | In pseudopolyneuritic ALS, only LMNs restricted 
to the distal limbs are involved. f | In hemiplegic ALS, unilateral UMN involvement 
with sparing of the face, and sometimes discrete LMN involvement, can be 
observed. g | In flail arm syndrome, LMN involvement is restricted to the upper 
limbs, but mild UMN signs can be detected in the legs. h | In flail leg syndrome, 
LMN involvement is restricted to the lower limbs, and is often asymmetric. 
Abbreviations: ALS, amyotrophic lateral sclerosis; LMN, lower motor neuron; UMN, 
upper motor neuron.
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poor prognosis.17–19 In some forms of ALS, such as the 
SETX-associated ALS type 4, the phenotype is so atypical 
that some authors suggest they should be considered as 
separate disease entities rather than ALS.20,21
60% of patients with disease onset between 20 and 
40 years of age have predominantly upper motor neuron 
involvement, and relatively few of these patients (15%) 
have bulbar-onset disease.15 Older age at onset is associ-
ated with decreased likelihood of upper motor neuron 
involvement (20%), increased probability of bulbar onset 
(some studies report up to 50% with onset after 80 years 
of age), and poor prognosis.9,22,23 Onset after 80 years is 
associated with a particularly short survival.16
Rate of progression
Although median survival in ALS is generally around 
3 years from diagnosis, variability in survival is remark-
able and reflects the variability in the rate of disease pro-
gression. The difference in individual rates of functional 
decline, even in small series of patients, demonstrates 
this high variability (Figure 3), and is one of the factors 
that complicate clinical trials in ALS.
At one end of this continuum are the 10% of patients 
who live longer than 10 years with ALS.16 At autopsy, their 
disease does not differ from classic ALS.24 Long survival 
is seen more frequently in patients with juvenile ALS and 
upper motor neuron-predominant ALS.16,23 Some forms 
of hereditary ALS are known to be associated with par-
ticularly long or short survival. For example, long survival 
has been reported in association with the SOD1 Asp90Ala 
mutation, whereas the SOD1 Ala4Val mutation can induce 
a very aggressive disease.1 Patients with a hexanucleotide 
(GGGGCC) expansion mutation in the C9orf72 gene have 
shorter survival than the average ALS patient.25–28
Even within families in which members carry the same 
mutation, variability in progression rates is large.29–31 This 
finding suggests that there is no straightforward relation-
ship between the genetic cause and phenotype but, rather, 
that factors—either genetic or e nvironmental—modify 
the phenotypic expression, and in particular age at onset 
and disease progression. It is important to identify these 
modifying factors, as they could be targets for therapeu-
tic intervention, even in the absence of knowledge of the 
cause of disease. Delaying age at onset or attenuating pro-
gression rate and, thus, functional decline is of obvious 
therapeutic interest. Several small animal models, such 
as Drosophila and zebrafish, have been used to screen 
for such modifiers, resulting in the identification of 
 ‘druggable’ targets or even novel causes of ALS.2
Motor neuron involvement
Lower motor neuron dominance
Evidence of both upper and lower motor neuron involve-
ment is required for the diagnosis of ALS, and has been 
incorporated in the so-called El Escorial criteria.32 Of 
note, however, these criteria were developed to reduce 
the phenotypic variability in clinical trials, and were not 
intended for clinical decision-making.
Assessing the involvement of upper motor neurons 
relies on clinical judgement—largely, evaluation of the 
briskness of deep tendon reflexes. Neurologists some-
times disagree on the interpretation of this measure: 
some consider a preserved reflex in an other wise atrophic 
muscle to be a sign of upper motor neuron involvement, 
while others require the reflex to be hyperactive to reach 
the same conclusion. A patient can, thus, be considered 
to have ALS by one clinician, and to have progressive 
 muscular atrophy (PMA) by another (Figures 2 and 4).
Progressive muscular atrophy
PMA refers to an adult-onset lower motor neuron dis-
order that differs from the rare instances of adult-onset 
spinal muscular atrophy (SMA) in several respects: PMA 
is usually asymmetric, can have distal and/or proximal 
onset, and progresses much faster than SMA.3 Thus, 
PMA essentially equals ALS minus (convincing) upper 
motor neuron findings. PMA is believed to constitute 
about 5% of all patients with motor neuron disease 
(MND).33 The question arises as to whether PMA and 
ALS have different pathophysiological backgrounds 
and thereby represent different disorders, or whether 
PMA represents the end of a spectrum of lower versus 
UMN signs
■ Babinski sign
■ Hyperreexia
■ Spasticity
■ Pseudobulbar affect
■ Exaggerated jaw or gag reex
■ Hoffman sign
Primary motor cortex (UMN)
Bulbar and spinal motor neurons (LMN)
Frontotemporal cortex
Ocular motor neurons
Vesicorectal motor neurons (Onuf’s nucleus)
LMN signs
■ Atrophy
■ Weakness
■ Fasciculations
■ Hyporeexia
 or areexia
Figure 2 | Preferential sites of neuronal involvement in ALS. UMNs in the primary 
motor cortex (blue) and bulbospinal LMNs (red) are the preferentially affected 
sites in ALS. Neurons in the frontotemporal cortex (orange), however, are 
frequently involved as well; the resulting phenotype will be in the frontotemporal 
dementia–ALS spectrum. Ocular (green) and vesicorectal (yellow) motor neuron 
involvement is rare, and happens mostly in cases of longstanding disease. 
Abbreviations: ALS, amyotrophic lateral sclerosis; LMN, lower motor neuron; UMN, 
upper motor neuron.
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upper motor neuron involvement (Figure 4). Support for 
the latter hypothesis comes from the finding that some 
SOD1 mutations give rise to a syndrome that primar-
ily affects lower motor neurons: patients with the SOD1 
Ala4Val mutation are classified as having ALS, but they 
lack upper motor neuron involvement.34,35 Furthermore, 
imaging studies have shown widespread, progressive 
frontal abnormalities in PMA that are similar to those in 
ALS,36,37 and postmortem studies of patients with lower 
motor neuron signs only often show classic lateral spinal 
cord involvement.38 Patients with PMA fare slightly 
better than those with clinical evidence of both lower 
and upper motor neuron involvement (see below).
Flail arm syndrome
Some patients have lower motor neuron involvement that 
remains limited to the upper limbs for at least 12 months 
(Figure 2). These limbs are often non-functional, while the 
lower limbs remain normal, although hyperreflexia and 
some hypertonia may be present.39,40 This variant is called 
flail arm syndrome (also referred to as the scapulo humeral 
form of ALS, Vulpian–Bernart syndrome, hanging arm 
syndrome, neurogenic man-in-a-barrel syndrome or 
brachial amyotrophic diplegia), and has a striking male 
predominance, with a male:female ratio of 4:1.40,41 After 
about 20 months, almost all patients with this syndrome 
develop more-widespread disease; the prognosis is some-
what better than that of classic ALS, with mean survival of 
4 years and long-term survival of 17%.6
Flail leg syndrome and dropped head syndrome
Even less frequent than flail arm syndrome is flail leg 
syndrome, characterized by often asymmetric, and pri-
marily distal, lower motor neuron involvement in the 
lower limbs for at least 12 months.41 Subtle upper motor 
neuron signs usually emerge over time,41,42 and after a 
mean of 16 months, the upper limbs and bulbar region 
also become affected.6 Progression is slightly slower 
than in classic ALS.6,41,42 Flail leg syndrome with mainly 
distal and bilateral involvement is also referred to as the 
‘pseudo polyneuritic’, ‘Marie–Patrikios’ or ‘peroneal’ form 
of ALS.41,42
Equally rare is onset in the cervical region, limited 
to the extensors of the neck, resulting in dropped head 
syndrome.43 Such clinical presentation needs to be 
differentiated from myasthenia gravis or a (typically 
 inflammatory) myopathy.
Upper motor neuron dominance
Some patients present with upper motor neuron findings 
only and, therefore, do not meet the standard criteria 
for ALS. These patients are considered to have primary 
lateral sclerosis (PLS); however, most of these individuals 
gradually develop lower motor neuron involvement.44,45 
The diagnosis of PLS can, therefore, only be made after 
a sufficiently long period of observation, as 23% of those 
who eventually develop lower motor neuron signs do so 
only after 4 years.44
PLS constitutes about 5% of all cases of MND.46 This 
condition is characterized by slower progression, more-
prolonged retention of functionality, sparing of respira-
tory function and less-severe weight loss than seen in 
ALS.47 Even in patients with PLS, lower motor neuron 
involvement is often evident at autopsy,46 which, together 
with the fact that known ALS-causing mutations can 
present with upper motor neuron involvement only,1 
suggests that PLS could be considered to be at one end 
of a spectrum of upper motor neuron involvement, with 
PMA being at the other end (Figure 4).
Interestingly, upper motor neuron involvement 
can be strikingly asymmetric. An extreme form is the 
unusual hemiplegic variant also called Mills syndrome or 
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Figure 3 | Variability of disease progression in ALS. ALSFRS scores of 30 randomly selected patients (Leuven University Hospital, 
Belgium) with ALS, from first visit to death. Patients with bulbar‑onset disease are indicated in red, patients with spinal‑onset 
disease are indicated in blue. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, ALS Functional Rating Scale.
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progressive hemiplegia.48,49 This form usually begins with 
unilateral upper motor neuron involvement in the lower 
limb, followed by slowly progressive ipsilateral involve-
ment of the arm, with relative sparing of the face. After a 
variable time period, the disease spreads to the initially 
unaffected side.
To conclude, several lines of evidence suggest that ALS, 
PMA and PLS are expressions of one biological entity: 
patients in the same family, or patients carrying mutations 
in the same ALS-associated allele, can have classic ALS, 
PMA or PLS; the clinical characteristics of a patient can 
vary over time; and detection of upper and lower motor 
neuron involvement depends on the method of assess-
ment. The main reason for distinguishing these pheno-
types is the difference in prognosis. Patients with isolated 
lower motor neuron involvement live only slightly longer 
than patients with clinical evidence of both upper and 
lower motor neuron involvement,50,51 whereas patients 
with PLS, on average, live longer than those with ALS.47 
The mean survival of ALS patients with predominant 
upper motor neuron signs—6 years, with about 30% of 
cases exhibiting long-term (>10 years) survival—lies 
between that of PLS and classic ALS.6,44 This differ-
ence may simply reflect the biological burden of disease 
(Figure 5). It also implies that the best approach is to 
study patients with both lower and upper motor neuron 
involvement only if one intends to (prognostically) 
homogenize a study population, as is needed, for example, 
in clinical trials that investigate the effects of a drug on 
function or survival.
Nonmotor involvement in ALS
ALS has long been believed to be a neurodegenerative dis-
order with isolated motor neuron involvement. Absence 
of cognitive deterioration was initially even postulated as a 
prerequisite for a diagnosis of ALS. Nowadays, however, it 
is evident that other neurological systems can be affected, 
with cognitive impairment being the most frequent 
 manifestation of nonmotor involvement.
Cognitive impairment
Over the past few decades, a spectrum of cognitive involve-
ment has been increasingly acknowledged as a part of 
ALS.52–54 Degenerative changes in layer V of the fronto-
temporal lobe represent the anatomical substrate of this 
cognitive decline, hence the name frontotemporal lobar 
degeneration (FTLD). Up to 25% of patients with ALS 
meet all criteria for the clinical manifestation of FTLD, 
frontotemporal dementia (FTD), mostly of the behav-
ioural variant.55,56 Mild to moderate frontal dysfunction 
or language abnormalities are even more frequent, but 
can escape routine clinical examination and be detected 
on detailed testing only. Apathy (seen in 60% of patients), 
disinhibition, delusions and stereotypic behaviour are the 
most frequently encountered behavioural changes.52,55 
Whether depression (reported in up to 75% of patients57) 
can also be attributed to the ALS pathology is difficult to 
judge, as patients have obvious reasons for reactive depres-
sion. It should be kept in mind that even mild frontal 
impairment can contribute to non-compliance with 
percutaneous endoscopic gastrostomy therapy and non-
invasive ventilation, difficulties handling communication 
machines, psycho social problems and decision-making, 
and undoubtedly increases caregiver burden.52,53
ALS–FTD spectrum
ALS is now accepted to constitute a continuum with FTD. 
Pure ALS (without any evident cognitive abnormality) and 
pure FTD (without any obvious motor abnormality) are 
located at the opposite ends of this spectrum (Figure 4). 
ALS patients with mild behavioural dysfunction are classi-
fied as having ALS with behavioural impairment (ALSbi),52 
whereas patients with mild executive and language dys-
function are said to have ALS with cognitive impairment 
(ALSci).52 Patients with ALS who meet the Neary criteria 
for FTD are considered to have ALS–FTD. Of note, up to 
50% of patients with a diagnosis of FTD have some motor 
neuron involvement (which may go unnoticed by the 
patient), and are said to have ‘FTD–MND’.52,54
In ALS, the onset of cognitive problems usually pre-
cedes that of motor dysfunction.53,54 Frontotemporal 
involvement can only become evident in retrospect, 
when motor problems bring the patient under medical 
attention. Interestingly, eye movement disorders, prob-
ably related to frontal network dysfunction, are especially 
prevalent in these patients.52
The prognosis of patients with subtle cognitive impair-
ment is similar to that in classic ALS,55 but patients with 
ALSbi or ALS–FTD have a worse prognosis than do 
patients with ALS alone.53 The life expectancy in ALS–
FTD is 2.4 years from disease onset, approximately 1 year 
a
c
b
PMA
ALS
Classic ALS ALS with multisystem degeneration
Extramotor involvement
FTDALS–FTD FTD-MNDALSci
ALSbi
ALS
LMN-predominant UMN-predominant
PLS
Figure 4 | ALS, a spectrum disorder. a | PMA (isolated LMN involvement) and PLS 
(isolated UMN involvement) constitute the ends of a spectrum of LMN and UMN 
involvement; intermediate phenotypes are considered to be different expressions 
of ALS. b | ALS and FTD constitute the ends of a spectrum of motor neuron and 
frontotemporal neuron involvement. This spectrum includes patients with ALS who 
express isolated ALSci or ALSbi, and patients with ALS who meet the Neary criteria 
for FTD and are, thus, diagnosed with ALS–FTD. Some patients with FTD have 
insufficient motor neuron involvement for a diagnosis of ALS, and are classified as 
FTD–MND. c | A spectrum of extramotor involvement is possible in ALS, ranging 
from classic ALS with no to mild extramotor involvement to ALS with extrapyramidal, 
cerebellar, sensory, autonomic, urinary or oculomotor involvement, designated as 
‘ALS with multisystem degeneration’. Abbreviations: ALS, amyotrophic lateral 
sclerosis; ALSbi, ALS with behavioural impairment; ALSci, ALS with cognitive 
impairment; FTD, frontemporal dementia; LMN, lower motor neuron; MND, motor 
neuron disease; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy; 
UMN, upper motor neuron.
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less than in pure ALS.58 Problems with compliance with 
therapy and support could contribute to this differ-
ence.52,59 Alternatively, the difference in prognosis might 
simply reflect the disease burden (Figure 4).
Lessons from C9orf72 expansions
The clinical observations discussed above establish a 
clear link between ALS and FTD. Pathogenic evidence 
for such link came from the observation that very similar 
aggregates containing TDP-43, among other proteins, 
can be found in brain tissue in the majority of patients 
with either FTD or ALS.60 However, it was the discovery 
of a hexanucleotide expansion mutation in the C9orf72 
gene—C9orf72(GGGGCC)exp—that unequivocally linked the 
two ends of the spectrum.61–63 This mutation under-
lies nearly half of cases of familial ALS and a quarter 
of cases of familial FTD.1 The pathogenic mechanisms 
underpinning the connection between C9orf72(GGGGCC)exp 
and ALS–FTD remain poorly understood, but the studies 
connecting the two have already changed our  perceptions 
of these neuro degenerative disorders.2
Patients with C9orf72(GGGGCC)exp-associated ALS show 
marked phenotypic variability. In patients from within 
the same family with a C9orf72 expansion, onset can be 
frontotemporal, bulbar or spinal.64,65 The length of the 
repeat section does not seem to correlate with the sever-
ity of disease or site of onset, and patients who are homo-
zygous for the mutation do not have more-severe disease 
than heterozygous patients.64 Bulbar onset is more fre-
quent in ALS patients with C9orf72(GGGGCC)exp than in 
those without.64 Interestingly, bulbar onset is (almost) 
never seen in mutant-SOD1-associated ALS, and cog-
nitive impairment is equally rare in patients with this 
mutation.12,66,67 It should be noted that cognitive assess-
ment in patients with bulbar failure can be challeng-
ing because of the speech problems and pseudobulbar 
affect that these patients experience, and instruments for 
bedside evaluation are still being developed.
The spectrum of neuropsychiatric symptoms associ-
ated with C9orf72(GGGGCC)exp-associated ALS is much 
broader than previously thought, even encompassing 
psychosis and depressive pseudodementia.53,64,65,68,69 
Furthermore, motor symptoms in these patients can be 
variable, manifesting as ataxia, parkinsonism or chorea 
(discussed below).
In conclusion, FTD and ALS form a spectrum, with 
‘pure ALS’ and ‘pure FTD’ at the extreme ends. The 
factors that modify the phenotypic expression and, 
thus, determine a patient’s position on that continuum 
are unknown. The biological basis of such a disease con-
tinuum is likely to be complex, which is already evident 
from the observation that the ‘FTD’ component seems 
to be susceptible to different modifying factors than the 
‘ALS’ component, as discussed below.
ALS as a multisystem degeneration
Although the symptoms and signs in an patient with ALS 
are predominantly motor in nature, it should be kept in 
mind that the lines defining neuro degenerative dis orders 
are blurring. Some evidence for this phe nomenon again 
comes from the study of C9orf72(GGGGCC)exp. This muta-
tion gives rise to clinical characteristics well beyond 
ALS–FTD: it can also manifest as cerebellar abnormali-
ties and autonomic dysfunction, leading to a diagnosis of 
multiple system atrophy, or as chorea and neuropsychi-
atric abnormalities, leading to a diagnosis of Huntington 
disease (HD).70,71
Surprisingly, some genes associated with ALS–FTD 
can also influence phenotypic traits that are not directly 
related to the function of the nervous system. Mutations 
in VCP, HNRNPA2B1 and HNRNPA1 can induce 
ALS and/or FTLD combined with inclusion body myo-
sitis and bone abnormalities, such as those seen in Paget 
disease.72,73 These phenotypes again demonstrate the 
multisystemic character of ALS.
Evidence for the widespread nature of ALS-induced 
pathology has also come from the careful clinical obser-
vation of patients with unusually long survival in the 
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Figure 5 | Disease severity correlates with extent of neuronal involvement. In ALS, 
UMN, LMN and frontotemporal neurons are affected to variable extents, resulting in a 
wide range of clinical representations and disease severity, which is reflected by large 
prognostic variability. The horizontal axis depicts the proportion of UMN versus LMN 
involvement, and frontotemporal involvement is depicted in the diagonal axis. Disease 
severity is depicted in the vertical axis, and correlates inversely with survival. In the 
UMN–LMN spectrum, pure UMN involvement, as in PLS (1), and pure LMN involvement, 
as in PMA (2) have a better prognosis than disease with both UMN and LMN 
involvement (3). Increasing frontotemporal involvement is associated with shortened 
survival. Degeneration of all three neuronal systems (4) is associated with the highest 
disease severity and, hence, the worst prognosis. Abbreviations: ALS, amyotrophic 
lateral sclerosis; FTD, frontotemporal dementia; LMN, lower motor neuron; PLS, 
primary lateral sclerosis; PMA, primary muscular atrophy; UMN, upper motor neuron.
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setting of sustained ventilatory and nutritional support. 
In these patients, eye movement abnormalities, auto-
nomic dysfunction and sensory involvement eventu-
ally become evident.74 In rare cases, such multisystem 
involvement is already apparent at disease onset, and 
sometimes the clinical presentation is so different from 
that of classic ALS that clinicians consider the patient to 
have a different disease. In the sections that follow, we 
discuss some of these presentations.
ALS with extrapyramidal involvement
Besides the endemic ALS–Parkinson dementia syn-
dromes of Guam75 and the Kii peninsula,76 extrapyra-
midal involvement can sometimes be observed in patients 
with ALS. ALS associated with Parkinson disease (PD) is 
known as Brait–Fahn–Schwartz syndrome or ALS–PD 
complex, and is very rare.77 The parkinsonism in these 
patients is usually typical for PD, including the response 
to levodopa.78 Onset of motor neuron dysfunction usually 
follows a few years later, but simultaneous onset has been 
reported.77,79 Progression is similar to that of classic ALS.78 
These rare patients are thought to have two separate dis-
eases, although mutations in PARK7 (also known as DJ1) 
have been reported to cause a PD–ALS–FTD syndrome, 
providing a possible genetic link.80
ALS–parkinsonism is much more common than ALS–
PD complex. ALS–parkinsonism refers to the presence 
of extrapyramidal findings that are unresponsive to levo-
dopa in patients with ALS. Mild parkinsonism is present 
in 5–15% of patients with ALS, and is typically character-
ized by postural instability and backward falls.78,81 In such 
patients, abnormalities in the nigro striatal system can be 
seen on dopamine transporter imaging or at autopsy.78,81–83 
In our experience, distinguishing the spastic, extrapy-
ramidal and frontal motor findings in such patients is not 
trivial, which could explain why different studies have 
reported variable frequencies of ALS–parkinsonism.
Chorea and/or hemiballismus can occur late in the 
disease course in rare cases of ALS.84,85 As mentioned 
above, chorea is seen in some patients with a C9orf72 
mutation. To date, about 15 cases of ALS–chorea— 
concomitant ALS and HD—have been reported.86 Most 
of these patients have late-onset (>50 years) HD, and 
developed ALS 5–10 years later.86 Neuropathological evi-
dence for motor neuron involvement has been reported 
in a subset of patients with HD.87
ALS and cerebellar ataxia
Ataxia is a rare finding in ALS. As mentioned above, it is 
known to occur in patients with C9orf72(GGGGCC)exp. In addi-
tion, a few patients with spino cerebellar ataxia (SCA) have 
been reported to develop rapidly progressive ALS in the 
late stage of their disease (SCA–ALS).70,88 Interestingly, 
SCA type 2, which is caused by a CAG expansion in 
ATXN2, has genotypic and phenotypic overlap with ALS. 
Intermediate-length expansions in ATXN2 are a risk factor 
for ALS—but, strangely enough—not for ALS–FTD or 
FTD89,90—and ATXN2 mutations can present as ALS.91 
The biological basis for the link between SCA and ALS 
is unknown.
ALS with sensory involvement
Subjective sensory symptoms are reported to occur in 
50%, and objective sensory signs in 10%, of patients 
with ALS, but a true sensory neuropathy is rare in ALS.92 
The SOD1D90A mutation gives rise to prominent sensory 
symptoms, with posterior column involvement evident 
at autopsy.14,93,94
ALS with urinary and autonomic involvement
Apart from patients with a C9orf72(GGGGCC)exp mutation,95 
symptoms indicative of autonomic nervous system 
involvement are rare in ALS, although specific testing 
can indicate subclinical involvement of cardiovascu-
lar, gastrointestinal and sudomotor systems, and the 
salivary and lacrimal gland.96,97 Bladder problems are 
commonly believed not to be a feature of ALS, because 
Onuf ’s nucleus is typically spared or only minimally 
affected.3 Of note, urinary incontinence and retention 
certainly do occur in patients with ALS, but these prob-
lems are usually attributed to the use of muscle relaxants 
and anticholinergics, or to the patient’s motor problems. 
However, it should be noted that patients with SOD1 
Asp90Ala mutations often have urinary symptoms,14,94 
and that urgency of micturition is a very frequent 
symptom of PLS, affecting 50–70% of patients.45,98
ALS with ophthalmoplegia
As mentioned above, ophthalmoplegia, resulting from 
widespread brainstem pathology, can be observed in 
very late stages of ALS, and is only seen in patients with 
unusually long survival; it very rarely occurs shortly after 
disease onset.
ALS with deafness
Deafness is not a feature of ALS or any of its genetic 
or phenotypic variants; however, it can be part of rare 
syndromes with ALS-like features, the most famous of 
which is Brown–Vialetto–Van Laere syndrome, a genetic 
disease caused by mutations in genes coding for ribo-
flavin transporters.99 This syndrome is closely related 
to Fazio–Londe syndrome, in which auditory function 
is spared.3
Summary
In summary, the extrapyramidal, cerebellar, sensory 
or autonomic systems are rarely affected by ALS, and 
usually only with advanced disease. Similarly, urinary 
and ocular motor neuron involvement is only seen in 
patients with very long survival and advanced disease. 
Disruption of these systems usually has limited clinical 
importance, but it confirms the viewpoint that ALS is a 
multi system neurological disease.
From biology to therapy
As described above, ALS has high phenotypic variability. 
Some of the phenotypic differences might be of a quanti-
tative rather than a qualitative nature, as their detection 
depends on the method of observation. For example, if 
sophisticated testing is used, all patients with ALS might 
show evidence of frontal dysfunction,100 and transcranial 
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magnetic stimulation of the cortex might uncover 
cortico spinal abnormalities that would go un noticed by 
a clinical examination.101
The molecular and cellular biology underlying the 
pheno typic variation remain elusive. Motor neurons 
seem strikingly vulnerable to ALS, those with a large 
diameter more so than small ones,102,103 whereas the 
oculomotor neurons and those in Onuf ’s nucleus are 
far more resistant. Why ALS starts in spinal neurons in 
some patients, but in bulbar neurons in others, remains 
puzzling. The large layer V neurons in the frontal and 
temporal cortex are generally less vulnerable than motor 
neurons, but in some patients this situation is reversed. 
Why do some patients with C9orf72(GGGGCC)exp develop 
ALS, whereas others develop FTD or ALS–FTD? Why 
do some patients with the SOD1 Gly93Cys mutations die 
after 2 years of disease, while others with the same muta-
tion survive for more than 20 years? Why do some indi-
viduals carrying a pathogenic SOD1 or C9orf72 mutation 
never get ALS or FTD? Are they resistant to the disease, 
or is their age at onset beyond the normal human lifespan?
Several factors contributing to different aspects of this 
vulnerability have been identified, but the pathophysio-
logical mechanisms remain poorly understood. The size 
of the motor neurons, the length of their axons, their 
metabolic rate and many other characteristics have been 
hypothesized as contributors, but never proven to have 
a role. Some evidence suggests that the low abundance 
of calcium buffering proteins104 and the presence of 
mitochondrial matrix metalloproteinase-9105 underlie 
the difference in vulnerability between oculomotor and 
other motor neurons.Expression of the ephrin type-A 
receptor 4 protein (encoded by EPHA4),106 as well as 
excitability characteristics,107 have been suggested to con-
tribute to the difference in vulnerability of large versus 
small motor neurons. Susceptibility of motor neurons to 
excito toxi city could explain why spinal sensory neurons 
are less vulnerable to ALS than are motor neurons.108 
Moreover, studies in SOD1 mutant mice suggest that 
the vulnerability of motor neurons is related to specific 
 excitability-related pathways in these cells.107
Polymorphisms in the UNC13A gene and expression 
levels of EPHA4 have been suggested to contribute to the 
variability in disease severity.106,109 ATXN2 expansions 
are a risk factor for ALS but not for FTD,90 whereas the 
TMEM106B risk allele is a risk factor for FTD but not 
for ALS.110 Phenotypic variability across the ALS–FTD 
spectrum (and probably other spectra) is, thus, believed 
to be largely due to various genetic polymorphisms with 
different cytotoxic or cytoprotective effects according 
to neuronal cell type. Better knowledge of these factors, 
whether they be environmental or genetic in nature, is 
important, as they could be targets for intervention, even 
in patients in whom the cause of the disease is unknown.
Conclusions
Since its initial description by Charcot, ALS has been con-
sidered to be a homogenous neurodegenerative disease 
with selective involvement of both upper and lower motor 
neurons. Progress in genetics and in precise phenotyp-
ing of ALS has revealed shortcomings in the 19th century 
semiological approach. Abundant evidence has redirected 
the view towards the concept of a hetero geneous multi-
system neurodegenerative disease. Cognitive impairment 
is thought to be an intrinsic characteristic of this disease, 
as reflected in the ALS–FTD spectrum. Involvement of 
upper and lower motor neurons forms a similar spec-
trum. Variability in clinical presentation, onset, duration 
and hereditability is considerable. Clinically relevant 
involvement of extra pyramidal, cerebellar, autonomic 
and sensory systems is rare, but shows ALS to be a 
 multisystem degeneration disorder.
Some of the clinical variability certainly depends on 
the method and timing of assessment, but the majority 
seems to reflect differences in vulnerability of neurons. 
Clinical, genetic and biological studies are underway 
to identify the factors that underlie this variability. It is 
unknown whether this variability also implies differen-
tial response to therapy. It remains to be seen whether all 
phenotypic presentations will respond to the same drug 
and, if so, to the same extent. Phenomics, genomics, pro-
teomics, metabolomics and other unbiased approaches 
will need to be brought together. Such approaches will 
require large sets of very carefully and uniformly pheno-
typed patient populations. Hopefully, such studies 
will allow the development of strategies to change the 
phenotypic expression of ALS and find a cure for this 
dreadful disease.
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